Johnson & Johnson CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Blinded Dry Mouth Spray Crossover Study
- Conditions
- XerostomiaHead and Neck CancerXerostomia Following Radiotherapy
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jonas Johnson
- Target Recruit Count
- 129
- Registration Number
- NCT04608773
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy
- Conditions
- Oral Pharyngeal CancerDysphagia
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Jonas Johnson
- Target Recruit Count
- 26
- Registration Number
- NCT02564887
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
News
Nipocalimab Demonstrates Significant Efficacy in Phase 2 Sjögren's Disease Trial Published in The Lancet
Johnson & Johnson's nipocalimab, a first-in-class FcRn blocker, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in disease activity scores at Week 24 versus placebo.
J&J's Rybrevant Shows 45% Response Rate in Head and Neck Cancer, Doubling Standard of Care
Johnson & Johnson's bispecific antibody Rybrevant demonstrated a 45% objective response rate in previously treated head and neck squamous cell cancer patients, doubling the response rates of current standard treatments.
Subcutaneous Amivantamab Shows 45% Response Rate in Recurrent Head and Neck Cancer
Johnson & Johnson's subcutaneous amivantamab demonstrated a 45% overall response rate in 38 patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma who had progressed on checkpoint inhibitors and platinum-based chemotherapy.
Johnson & Johnson Eyes Full Acquisition of Protagonist Therapeutics Following Successful Icotrokinra Partnership
Johnson & Johnson is reportedly considering a complete acquisition of partner Protagonist Therapeutics, following years of successful collaboration on the first-in-class oral peptide icotrokinra for immune-mediated diseases.
Johnson & Johnson to Spin Off $9.2 Billion Orthopedics Business as DePuy Synthes
Johnson & Johnson announced plans to spin off its orthopedics business into a standalone company called DePuy Synthes within 18-24 months, generating $9.2 billion in fiscal year 2024 sales.
Ona Therapeutics Appoints ADC Development Veteran Dr. Antoine Yver as Board Chair to Advance Breast Cancer Pipeline
Ona Therapeutics has appointed Dr. Antoine Yver, a veteran with over 35 years of oncology drug development experience, as Chair of its Board of Directors to guide the company's transition to clinical-stage operations.
FDA Adds Boxed Warning to Carvykti for Fatal Gastrointestinal Complications
The FDA has approved labeling changes for Johnson & Johnson and Legend Biotech's CAR-T therapy Carvykti to include a boxed warning for immune effector cell-associated enterocolitis (IEC-EC), a potentially fatal gastrointestinal condition.
Johnson & Johnson in Acquisition Talks with Protagonist Therapeutics Following Positive Ulcerative Colitis Trial Results
Johnson & Johnson is reportedly in discussions to acquire Protagonist Therapeutics, sending PTGX shares soaring over 30% on Friday despite no confirmed deal details.
Johnson & Johnson in Advanced Acquisition Talks with Protagonist Therapeutics for $4.2 Billion Deal
Johnson & Johnson is in discussions to acquire Protagonist Therapeutics, which has a market capitalization of $4.2 billion as of Thursday's close.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.